Clinical trial
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
NCT00162123 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00162123 |
|---|---|
| Title | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies |
| Official title | A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols. |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab |
| Enrollment | 248 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Apr 1, 2014 |
| First posted | Sep 13, 2005 |
| Last update posted | Jul 27, 2016 |
| Countries | Argentina, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Norway and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: